THALOMID Reviews (THALIDOMIDE)

Average Rating: 4.2 (4 Ratings)

Filter Results

Compare THALOMID with similar:
 IMMUNOMODULATORS

 Type: Rx Drug

  

THALOMID  (THALIDOMIDE):  This medication is used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). Thalidomide is also used to treat a certain type of cancer (multiple myeloma). It works in Hansen's disease by reducing swelling and redness (inflammation). It also reduces the formation of blood vessels that feed tumors.   FDA Approval Date: 2003-01-17 (Sources: U.S. Centers for Medicare Services, FDA)

  

Results are sorted by Date added.

Key to Ratings: 1=LOW (I would not recommend taking this medicine.)
5=HIGH (this medicine cured me or helped me a great deal.)

Page: 1


RATING  REASONSIDE EFFECTS FOR THALOMIDCOMMENTSSEXAGEDURATION/
DOSAGE
DATE ADDED
 
 4  Langerhans Histiocytosis Numbness in hands and feet. Mussel soreness and cramping in legs and feet. Swelling in legs and feet. Constipation. Systoms did not go away after not taking for a week. Currently on 50MG but have taken 100 and 200. F 63 3 years
10/11/2006
 3  Multiple Myeloma Rash on both calves, numbness/tingling in right arm, trembling hands, constipation A fairly good sedative M 63 60 days
2/22/2005
 5  Discoid Lupus No side effects other than sleepy with dosage of 100mg or above. The skin condition has completely cleared. I am now able to go into the sun. F 64 3 months
11/15/2004
 5  multiple myeloma constipation, tingleing in the feet, drowsy. It brought my multiple myeloma into remission. M 66 6 months
9/2/2004
Email
  

THALOMID  (THALIDOMIDE):  This medication is used to treat or prevent certain skin conditions related to Hansen's disease, once known as leprosy (erythema nodosum leprosum). Thalidomide is also used to treat a certain type of cancer (multiple myeloma). It works in Hansen's disease by reducing swelling and redness (inflammation). It also reduces the formation of blood vessels that feed tumors.   FDA Approval Date: 2003-01-17 (Sources: U.S. Centers for Medicare Services, FDA)

     

BACK TO TOP